Funds advised by Apax Partners announced that an entity controlled by them entered into a definitive agreement to acquire:
• The operating subsidiaries of Invent Farma S.L., a leading Spanish pharmaceutical company, from a consortium of investors led by Silfurberg, Framtakssjóður Íslands (Enterprise Investment Fund) and Horn II.
Located in Barcelona, Invent Farma develops, manufactures and markets generic drugs. It owns and operates manufacturing plants in Spain and comprises three divisions:
– Inke, a manufacturer of active pharmaceutical ingredients (APIs) which has a unique expertise in the respiratory area
– Lesvi, a highly flexible manufacturer of finished dosage forms (FDFs) that has capabilities across multiple therapeutic areas
– Qualigen, which markets generic drugs in Spain and has a leading and rapidly growing franchise in the central nervous system (“CNS”) field
• neuraxpharm Arzneimittel GmbH, a leading German pharmaceutical company, from ATAX GmbH and Neuraxpharm Holding.
Located in Langenfeld near Düsseldorf, neuraxpharm is a leader in generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). Founded in 1985, the company is a trusted brand for neurologists, psychiatrists, pharmacists and patients. It has a portfolio of 100 predominantly differentiated products to serve the needs of CNS patients.
Terms of the transactions were not disclosed.